ES2421885T3 - Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia - Google Patents

Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia

Info

Publication number
ES2421885T3
ES2421885T3 ES08021660T ES08021660T ES2421885T3 ES 2421885 T3 ES2421885 T3 ES 2421885T3 ES 08021660 T ES08021660 T ES 08021660T ES 08021660 T ES08021660 T ES 08021660T ES 2421885 T3 ES2421885 T3 ES 2421885T3
Authority
ES
Spain
Prior art keywords
polypeptides
antibodies
patients
procedure
specific detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08021660T
Other languages
English (en)
Inventor
Lars Komorowski
Christian Probst
Anthonina Janssen
Winfried Stoecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euroimmun Medizinische Labordiagnostika AG
Original Assignee
Euroimmun Medizinische Labordiagnostika AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2421885(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euroimmun Medizinische Labordiagnostika AG filed Critical Euroimmun Medizinische Labordiagnostika AG
Application granted granted Critical
Publication of ES2421885T3 publication Critical patent/ES2421885T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Proteína que comprende un primer polipéptido de OspC, caracterizada porque el primer polipéptido de OspC está unidoa través de un puente disulfuro con un segundo polipéptido de OspC, formándose el puente disulfuro por unión de unacisteína que no está alejada más de 100 posiciones de aminoácidos del extremo N-terminal del polipéptido de OspC,presentando el primer y el segundo polipéptido de OspC una identidad de aminoácidos de al menos el 70% con la SEC IDNº: 3, SEC ID Nº: 6 o SEC ID Nº: 9.
ES08021660T 2008-12-12 2008-12-12 Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia Active ES2421885T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08021660.9A EP2199303B1 (de) 2008-12-12 2008-12-12 Polypeptide und Verfahren zur spezifischen Detektion von Antikörpern bei Patienten mit einer Borrelieninfektion

Publications (1)

Publication Number Publication Date
ES2421885T3 true ES2421885T3 (es) 2013-09-06

Family

ID=40568393

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08021660T Active ES2421885T3 (es) 2008-12-12 2008-12-12 Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia

Country Status (4)

Country Link
US (2) US8163500B2 (es)
EP (1) EP2199303B1 (es)
ES (1) ES2421885T3 (es)
PL (1) PL2199303T3 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2959971A1 (de) 2014-06-27 2015-12-30 Euroimmun Medizinische Labordiagnostika AG Verfahren und Vorrichtung zur Überführung von Flüssigkeiten
WO2016049148A1 (en) 2014-09-24 2016-03-31 Wellstat Diagnostics, Llc Compositions and methods for te diagnosis of lyme disease
EP4494756A1 (de) 2023-07-19 2025-01-22 Euroimmun Medizinische Labordiagnostika AG Vorrichtung und laborautomat zur inkubation von mehreren patientenproben unter verwendung mehrerer inkubationsgefässe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0506868T4 (da) 1989-12-22 2004-04-26 Mikrogen Molekularbiol Entw Immunologisk aktive proteiner fra Borrelia burgdorferi, tilhørende testkits og vaccine
US5620862A (en) * 1993-11-24 1997-04-15 University Of Connecticut Methods for diagnosing early Lyme disease
PT832093E (pt) 1995-06-07 2006-12-29 Sanofi Pasteur Inc Expressão de lipoproteínas
DE69718903T2 (de) 1996-05-02 2003-12-04 Dakocytomation Denmark A/S, Glostrup Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden
AT405940B (de) * 1996-06-21 1999-12-27 Immuno Ag Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein

Also Published As

Publication number Publication date
EP2199303B1 (de) 2013-06-05
US20100150964A1 (en) 2010-06-17
EP2199303A1 (de) 2010-06-23
US20120177680A1 (en) 2012-07-12
PL2199303T3 (pl) 2013-11-29
US8163500B2 (en) 2012-04-24
US8431135B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
AR123908A2 (es) Proteínas de fusión para tratar trastorno metabólicos
ES2545895T3 (es) Proteína de fusión anticancerígena
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
NO20063026L (no) Antistoffer
EA201491049A1 (ru) Противораковый слитый белок
PE20100054A1 (es) Inmunoglobulina con dominio variable dual
MX389347B (es) Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
ES2531288T3 (es) Proteína de fusión anticancerígena
UA103774C2 (uk) Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
EA201100072A1 (ru) Новые композиции и способы
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
EA201491277A1 (ru) Противораковый слитый белок
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
MX340772B (es) Medios y metodos para fabricar neurotoxina altamente pura.
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
BR112013025975A2 (pt) proteína de fusão anticancerígena
AR132574A2 (es) UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA
CY1111630T1 (el) Παραγωγα κυτοκινων
WO2008105178A1 (ja) リポソーム用生体成分抵抗性増強剤及びこれにより修飾されたリポソーム
ES2421885T3 (es) Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia
MX2010010213A (es) Peptido parcial de lacritina.
MX2018002616A (es) Proteina de fusion.
NZ589365A (en) Peptidyl diacylglycerides